Skip to main content
Fig. 4 | BMC Urology

Fig. 4

From: ♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study

Fig. 4

Construction of FUSCC cohort and drug efficacy. Patients in high risk group shows both poor PFS (A) and OS (B) than patients in low and intermediate risk group (p < 0.0001). C, D ROC curves indicates that the FUSCC model has high sensitivity and specificity to predict the recurrence/metastasis risk (AUC = 0.897) and cancer specific mortality (AUC = 0.932) of renal eAML patients. E The waterfall plot shows the best efficacy and reduction of the target lesion after Everolimus targeted treatment in 21 renal eAML patients with recurrence/metastasis, of which, the best response for Everolimus targeted treatment was 8/21 (38.1%) PR, 9/21 (42.9%) SD and 4/21 (19.0%) PD. F The representative imaging figures from one PR case (left: baseline CT imaging; right: 6 months after treatment) and one case of SD (right: baseline MRI imaging; right: 4 months after treatment

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us